Literature DB >> 9208137

Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16 on neurotensin-induced analgesia and neuronal inactivation.

B Vincent1, J Jiracek, F Noble, M Loog, B Roques, V Dive, J P Vincent, F Checler.   

Abstract

1. We have examined a series of novel phosphinic peptides as putative potent and selective inhibitors of endopeptidase 3.4.24.16. 2. The most selective inhibitor, Pro-Phe-psi(PO2CH2)-Leu-Pro-NH2 displayed a Ki value of 12 nM towards endopeptidase 3.4.24.16 and was 5540 fold less potent on its related peptidase endopeptidase 3.4.24.15. Furthermore, this inhibitor was 12.5 less potent on angiotensin-converting enzyme and was unable to block endopeptidase 3.4.24.11, aminopeptidases B and M, dipeptidylaminopeptidase IV and proline endopeptidase. 3. The effect of Pro-Phe-psi(PO2CH2)-Leu-Pro-NH2, in vitro and in vivo, on neurotensin metabolism in the central nervous system was examined. 4. Pro-Phe-psi(PO2CHH2)-Leu-Pro-NH2 dose-dependently inhibited the formation of neurotensin 1-10 and concomittantly protected neurotensin from degradation by primary cultured neurones from mouse embryos. 5. Intracerebroventricular administration of Pro-Phe-psi(PO2CH2)-Leu-Pro-NH2 significantly potentiated the neurotensin-induced antinociception of mice in the hot plate test. 6. Altogether, our study has established Pro-Phe-psi(PO2CH2)-Leu-Pro-NH2 as a fully selective and highly potent inhibitor of endopeptidase 3.4.24.16 and demonstrates, for the first time, the contribution of this enzyme in the central metabolism of neurotensin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208137      PMCID: PMC1564740          DOI: 10.1038/sj.bjp.0701182

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Structure of neurolysin reveals a deep channel that limits substrate access.

Authors:  C K Brown; K Madauss; W Lian; M R Beck; W D Tolbert; D W Rodgers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

2.  Mapping sequence differences between thimet oligopeptidase and neurolysin implicates key residues in substrate recognition.

Authors:  Kallol Ray; Christina S Hines; David W Rodgers
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

3.  Allosteric inhibition of the neuropeptidase neurolysin.

Authors:  Christina S Hines; Kallol Ray; Jack J Schmidt; Fei Xiong; Rolf W Feenstra; Mia Pras-Raves; Jan Peter de Moes; Jos H M Lange; Manana Melikishvili; Michael G Fried; Paul Mortenson; Michael Charlton; Yogendra Patel; Stephen M Courtney; Chris G Kruse; David W Rodgers
Journal:  J Biol Chem       Date:  2014-11-05       Impact factor: 5.157

4.  Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Authors:  Naomi J Wangler; Kira L Santos; Ines Schadock; Fred K Hagen; Emanuel Escher; Michael Bader; Robert C Speth; Vardan T Karamyan
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 5.  Neurolysin: From Initial Detection to Latest Advances.

Authors:  Frédéric Checler; Emer S Ferro
Journal:  Neurochem Res       Date:  2018-08-29       Impact factor: 3.996

6.  Neurolysin knockout mice generation and initial phenotype characterization.

Authors:  Diogo M L P Cavalcanti; Leandro M Castro; José C Rosa Neto; Marilia Seelaender; Rodrigo X Neves; Vitor Oliveira; Fábio L Forti; Leo K Iwai; Fabio C Gozzo; Mihail Todiras; Ines Schadock; Carlos C Barros; Michael Bader; Emer S Ferro
Journal:  J Biol Chem       Date:  2014-04-09       Impact factor: 5.157

7.  Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth.

Authors:  Thaysa Paschoalin; Adriana K Carmona; Elaine G Rodrigues; Vitor Oliveira; Hugo P Monteiro; Maria A Juliano; Luiz Juliano; Luiz R Travassos
Journal:  Mol Cancer       Date:  2007-07-09       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.